IOB - Delayed Quote USD

Amgen Inc. (0R0T.IL)

272.50

-0.50

(-0.18%)

At close: 7:09:05 PM GMT+1

2 Unstoppable Dividend Stocks to Buy and Hold Forever

Amgen is an innovative leader in an industry where its products will always be in high demand. Microsoft is navigating the current situation well and boasts lucrative growth opportunities. Two excellent options right now are Amgen (NASDAQ: AMGN) and Microsoft (NASDAQ: MSFT).

Motley Fool 7 hours ago

MSFT

AMGN
Amgen Inc. (AMGN): A Bull Case Theory

We came across a bullish thesis on Amgen Inc. (AMGN) on Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on AMGN. Amgen Inc. (AMGN)’s share was trading at $281.22 as of May 2nd. AMGN’s trailing and forward P/E were 25.64 and 13.48 respectively according to Yahoo Finance. Amgen (AMGN) delivered a strong […]

Insider Monkey yesterday

AMGN
Is Amgen Inc. (AMGN) the Best Dow Stock?

We recently published a list of The Best and Worst Dow Stocks. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other Dow stocks. The Dow Jones Industrial Average is a benchmark index of the top 30 companies in the US. It represents the strength of the […]

Insider Monkey yesterday

AMGN
Here's Why Amgen (AMGN) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks yesterday

AMGN
Here's Why Amgen (AMGN) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 2 days ago

AMGN
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Zacks 3 days ago

AMGN
AMGN's Key Drugs Repatha, Evenity & Blincyto Drive Q1 Sales Growth

AMGN's 14 products, including Repatha, Blincyto, Tezspire, Tavneos and Evenity, achieve double-digit volume growth in the first quarter.

Zacks 3 days ago

AMGN
Amgen (NasdaqGS:AMGN) Reports Strong Q1 Earnings With Revenue Increase To US$8 Billion

Amgen (NasdaqGS:AMGN) recently reported strong financial results for Q1 2025, showing a turnaround from a loss to a substantial net income. This positive performance included ambitious revenue and earnings guidance for the year, likely adding weight to the broader market's upward trend, as reflected in a 1.41% price increase. The expansion of the company's manufacturing capabilities and stable share buyback updates may have further supported investor confidence. During this time, broader...

Simply Wall St. 6 days ago

AMGN
Amgen’s Stelara biosimilar gets off to fast start

Sales of the company’s copycat to J&J’s blockbuster reached $150 million in the first quarter, adding to a surge in revenue for Amgen's biosimilar business.

BioPharma Dive 6 days ago

AMGN
Q1 2025 Amgen Inc Earnings Call

Q1 2025 Amgen Inc Earnings Call

Thomson Reuters StreetEvents 6 days ago

AMGN
Amgen's Q1 Earnings Beat Estimates, Key Drugs Drive Sales Growth

AMGN beats first-quarter estimates for earnings and sales. Sales of most of its products, Prolia, Xgeva, Repatha, Blincyto and Evenity beat estimates.

Zacks 6 days ago

AMGN

AZN
Amgen Inc (AMGN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Pricing Challenges

Amgen Inc (AMGN) reports a robust 9% revenue increase driven by key brands, despite facing pricing pressures and strategic challenges.

GuruFocus.com 6 days ago

AMGN
Compared to Estimates, Amgen (AMGN) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks 6 days ago

AMGN
Amgen (AMGN) Tops Q1 Earnings and Revenue Estimates

Amgen (AMGN) delivered earnings and revenue surprises of 17.79% and 2.47%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 7 days ago

AMGN
Amgen beats Q1 expectations, issues solid full-year outlook

Investing.com - Amgen Inc (NASDAQ:AMGN) reported better-than-expected first-quarter results, driven by strong demand for its products globally.

Investing.com 7 days ago

AMGN
Amgen posts profit, says tax policy more effective than tariffs

(Reuters) -Amgen on Thursday said its first-quarter profit rose 24%, driven by product sales, and said that while it is premature to speculate on the impact of U.S. tariffs, tax policy would be a more effective way to influence U.S. manufacturing. President Donald Trump's administration has opened a national security investigation into pharmaceuticals in a bid to demonstrate why the U.S. needs tariffs to increase domestic manufacturing. "We agree with our peers that the most effective answer is not tariffs, but tax policy," Amgen CFO Peter Griffith said on a conference call.

Reuters 7 days ago

AMGN
Amgen beats Q1 earnings, revenue estimates. Stock flat.

Amgen (AMGN) eked past first quarter revenue estimates, posting $8.15 billion (vs. estimates of $8.05 billion), while blowing past adjusted earnings per share forecasts with a figure of $4.90 (vs. estimates of $4.25). Yahoo Finance senior health reporter Anjalee Khemlani comes on Market Domination Overtime to dive deeper into these numbers. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.

Yahoo Finance Video 7 days ago

AMGN
Amgen: Q1 Earnings Snapshot

AMGN) on Thursday reported first-quarter net income of $1.73 billion, after reporting a loss in the same period a year earlier. On a per-share basis, the Thousand Oaks, California-based company said it had net income of $3.20. Earnings, adjusted for non-recurring costs, came to $4.90 per share.

Associated Press Finance 7 days ago

AMGN
Amgen’s (NASDAQ:AMGN) Q1: Beats On Revenue

Biotech company Amgen (NASDAQ:AMGN) announced better-than-expected revenue in Q1 CY2025, with sales up 9.4% year on year to $8.15 billion. The company expects the full year’s revenue to be around $35 billion, close to analysts’ estimates. Its non-GAAP profit of $4.90 per share was 15% above analysts’ consensus estimates.

StockStory 7 days ago

AMGN
AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2025.

PR Newswire 7 days ago

AMGN

Performance Overview

Return	0R0T.IL	S&P 500 (^GSPC)
YTD	+5.75%	-3.70%
1-Year	+4.52%	+9.18%
3-Year	+27.13%	+37.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Amgen Inc. (0R0T.IL)

2 Unstoppable Dividend Stocks to Buy and Hold Forever

Amgen Inc. (AMGN): A Bull Case Theory

Is Amgen Inc. (AMGN) the Best Dow Stock?

Here's Why Amgen (AMGN) is a Strong Growth Stock

Here's Why Amgen (AMGN) is a Strong Value Stock

Is Trending Stock Amgen Inc. (AMGN) a Buy Now?

AMGN's Key Drugs Repatha, Evenity & Blincyto Drive Q1 Sales Growth

Amgen (NasdaqGS:AMGN) Reports Strong Q1 Earnings With Revenue Increase To US$8 Billion

Amgen’s Stelara biosimilar gets off to fast start

Q1 2025 Amgen Inc Earnings Call

Amgen's Q1 Earnings Beat Estimates, Key Drugs Drive Sales Growth

Amgen Inc (AMGN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Pricing Challenges

Compared to Estimates, Amgen (AMGN) Q1 Earnings: A Look at Key Metrics

Amgen (AMGN) Tops Q1 Earnings and Revenue Estimates

Amgen beats Q1 expectations, issues solid full-year outlook

Amgen posts profit, says tax policy more effective than tariffs

Amgen beats Q1 earnings, revenue estimates. Stock flat.

Amgen: Q1 Earnings Snapshot

Amgen’s (NASDAQ:AMGN) Q1: Beats On Revenue

AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

Performance Overview